US20010046996A1 - Use of a compound for preparing a drug - Google Patents
Use of a compound for preparing a drug Download PDFInfo
- Publication number
- US20010046996A1 US20010046996A1 US09/784,302 US78430201A US2001046996A1 US 20010046996 A1 US20010046996 A1 US 20010046996A1 US 78430201 A US78430201 A US 78430201A US 2001046996 A1 US2001046996 A1 US 2001046996A1
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- group
- positions
- lower alkyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title abstract description 11
- 239000003814 drug Substances 0.000 title abstract description 11
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 18
- 239000001257 hydrogen Substances 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 6
- 150000002367 halogens Chemical class 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 4
- OIVUHPTVQVCONM-UHFFFAOYSA-N 6-bromo-4-methyl-1h-indazole Chemical compound CC1=CC(Br)=CC2=C1C=NN2 OIVUHPTVQVCONM-UHFFFAOYSA-N 0.000 claims abstract description 3
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000002253 acid Substances 0.000 claims abstract description 3
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims abstract description 3
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims abstract description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000001424 substituent group Chemical group 0.000 claims abstract description 3
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- VMWJCFLUSKZZDX-UHFFFAOYSA-N n,n-dimethylmethanamine Chemical group [CH2]N(C)C VMWJCFLUSKZZDX-UHFFFAOYSA-N 0.000 claims 9
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- FPLSGFJELWCFTH-UHFFFAOYSA-N 2-(2,3-dimethylindolo[3,2-b]quinoxalin-6-yl)-n,n-dimethylethanamine Chemical compound CC1=C(C)C=C2N=C3N(CCN(C)C)C4=CC=CC=C4C3=NC2=C1 FPLSGFJELWCFTH-UHFFFAOYSA-N 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 5
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 5
- 0 *C(C)N1c2ccccc2-c2nc3ccccc3nc21.CC.CC Chemical compound *C(C)N1c2ccccc2-c2nc3ccccc3nc21.CC.CC 0.000 description 4
- 102000003996 Interferon-beta Human genes 0.000 description 4
- 108090000467 Interferon-beta Proteins 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960001388 interferon-beta Drugs 0.000 description 4
- 231100000706 no observed effect level Toxicity 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 108010072051 Glatiramer Acetate Proteins 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- ZUNBGWZFZVZJHX-UHFFFAOYSA-N 2-(2,3-dimethyl-6h-indolo[2,3-b]quinoxalin-1-yl)-n,n-dimethylethanamine Chemical compound N1C2=NC3=CC=CC=C3C2=NC2=C1C=C(C)C(C)=C2CCN(C)C ZUNBGWZFZVZJHX-UHFFFAOYSA-N 0.000 description 1
- NXOVZLREWXNIDP-UHFFFAOYSA-N 7h-pyrazino[2,3-c]carbazole Chemical class N1=CC=NC2=C3C4=CC=CC=C4NC3=CC=C21 NXOVZLREWXNIDP-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- CMRPZCYHPJMCKM-UHFFFAOYSA-N CC1=CC2=C(C=C1C)N=C1C(=N2)C2=C(C=CC=C2)N1CCN(C)C.II Chemical compound CC1=CC2=C(C=C1C)N=C1C(=N2)C2=C(C=CC=C2)N1CCN(C)C.II CMRPZCYHPJMCKM-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010005716 Interferon beta-1a Proteins 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 229940021459 betaseron Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 229940038717 copaxone Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
Definitions
- the present invention relates to the use of a compound of the general formula I
- MS is a chronic disease with its origin in the central nervous system (CNS) that often leads to severe consequences. MS can be mild with minor symptoms to severe paralysis and loss of vision. The diagnosis is most common between the ages of 20 to 40 and thereafter the disease continues the remaining life span. Sometimes MS develops rapidly, while in other cases the afflicted persons can live for many decades only with some disabilities.
- CNS central nervous system
- MS is more frequent at northern latitudes. Depending on region in the western world the prevalence varies with 50-150 cases per 100,000. In the US only, some 250,000-350,000 have the MS diagnosis. Females have a double risk, compared to males, to develop MS.
- Interferon-beta (trademarks Avonex R and Betaseron R ) can reduce the symptoms among certain groups of patients and is therefore administered to most patients for ethical reasons. The effect is unclear for the population of MS patients and it is a very expensive treatment.
- Glatiramer acetate (trademark Copaxone R ) can for some patients reduce the frequence of attacks, but the side effects are substantial and there is a problem to distinguish the symptoms of the MS disease and side effects.
- MS is a rather common disease that appears early in life. In addition it is a life long disease with severe symptoms. The demand for drugs that can protect the MS patients for the severe development of the disease is therefore of high priority.
- the compound which according to the present invention is to be used for preparing a drug for treatment of MS is a compound of the following general formula I
- R 1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R 1 can be a hydroxyl group;
- X is a group —(CH 2 ) n —R 2 , wherein R 2 represents a nitrogen containing basic residue such as NH 2 , NHR 4 or NR 5 R 6 , wherein R 4 , R 5 and R 6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R 3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide.
- R 1 is preferably selected from hydrogen and lower alkyl groups, especially methyl. More preferably R 1 is methyl in positions 2 and 3 and hydrogen in the other positions. Suitable compounds are such compounds wherein R 1 is hydroxy in one of the positions 7-10, especially in position 9.
- a compound which has proven to be especially effective is the compound of the following formula II
- FIG. 1 shows the results obtained in an EAE model test.
- FIG. 2 shows the results obtained in an EAE rat model test with different doses of a compound used according to the present invention.
- FIG. 3 shows the effect of pre-treatment with a compound used according to the present invention.
- FIG. 4 shows the effect of after-treatment with a compound used according to the present invention.
- the EAE (experimental autoimmune encephalomyelitis) model is a generally accepted animal model for the acute MS symptoms ( (1) Ruuls et al, J. Immunology, 1996, 157, 5721-5731; (2) van der Medide et al, J. Neuroimmunology, 1998, 84, 14-23; (3) Smith et al, Nature Medicine,2000, 6, 1, 62-66).
- the model is based on Lewis rats that day 0 are induced by 20 ⁇ g myeline peptide (MBP 68-86) och 2 mg of Myobacterium tuberculosis. After one week severe CNS symptoms appear that are by double blind examination given a value—a clinical score. The higher value, the more severe effect.
- the scale is 0-5. After some 14 days there is a peak in symptoms followed by a decline back to the normal situation.
- the negative control has no treatment except the immunization (day 0) to induce the acute MS response.
- FIG. 1 the results from the negative control, Interferon-beta and a compound used according to the present invention, 2,3-dimethyl(dimethylaminoethyl)-5H-indolo-(2,3-b)quinoxaline, (B-220) are shown. From the figure it can be seen that Interferon-beta has no reducing effect of the CNS symptoms.
- the lower curve represents the tested substance used according to the present invention, which substance surprisingly and unexpectedly reduces the CNS symptoms with 2/3.
- NOEL intravenous, rat; 12.5 mg/kg bw
- NOEL cutaneous, rabbit; 200 mg/kg bw
- FIG. 3 pre-treatment with B-220 before the onset of the disease is shown.
- the highest curve is illustrating the control without any added B-220 while the lower curve is after administration of B-220 of 6 mg/animal.
- the pre-treatment results in a clear lowered and delayed MS effect.
- Administration of B-220 was from ⁇ 7 to +7 days in relation to the onset of disease (day 0).
- a suitable dosage range for humans is 1 to 50 mg/kg body weight.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Use of a compound of formula I
wherein R1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group;
X is a group —(CH2)n—R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide, for preparing a drug for treatment of MS (multiple sclerosis).
Description
- The present invention relates to the use of a compound of the general formula I
- for preparing a drug for treatment of MS (multiple sclerosis).
- MS is a chronic disease with its origin in the central nervous system (CNS) that often leads to severe consequences. MS can be mild with minor symptoms to severe paralysis and loss of vision. The diagnosis is most common between the ages of 20 to 40 and thereafter the disease continues the remaining life span. Sometimes MS develops rapidly, while in other cases the afflicted persons can live for many decades only with some disabilities.
- MS is more frequent at northern latitudes. Depending on region in the western world the prevalence varies with 50-150 cases per 100,000. In the US only, some 250,000-350,000 have the MS diagnosis. Females have a double risk, compared to males, to develop MS.
- It is generally accepted that the immune defense of a patient with MS attacks the CNS, while the exact mechanisms are unknown. Due to inflammation of the nerve isolation (myeline) there are dysfunctions and short-circuits of nerve fibers and thereby effects on the muscles controlled by these nerves.
- The treatment of MS is focused on the reduction of symptoms. To cure or stop the MS disease is not possible with today's knowledge. Consequently there does not exist any drug to cure or delay onset of the disease. Treatments used are:
- #Transplantation of bone marrow and treatment of cytostatics and lifelong administration of immunosupressive drugs. This method could work for some patients but it is very expensive and includes several risks for the patient. Administration of cytostatics is still considered to be controversial in treatment of MS since the effects are unclear and potential side-effects are severe.
- #There are two drugs used with the aim to cure or delay the MS disease; Interferon-beta (trademarks Avonex R and BetaseronR) can reduce the symptoms among certain groups of patients and is therefore administered to most patients for ethical reasons. The effect is unclear for the population of MS patients and it is a very expensive treatment.
- Glatiramer acetate (trademark Copaxone R) can for some patients reduce the frequence of attacks, but the side effects are substantial and there is a problem to distinguish the symptoms of the MS disease and side effects.
- Today there does not exist an effective treatment for MS. The treatment is focused on reducing symptoms. Tests with transplantation and different drug treatments to cure the disease have so far not shown any solutions. It can work for some patients, although there are risks, side effects and very high costs involved. MS is a rather common disease that appears early in life. In addition it is a life long disease with severe symptoms. The demand for drugs that can protect the MS patients for the severe development of the disease is therefore of high priority.
- According to the present invention it has surprisingly been found that a substituted indolo-quinoxaline of the following general formula I can be used for preparing a drug for treatment of MS.
- The compound which according to the present invention is to be used for preparing a drug for treatment of MS is a compound of the following general formula I
- wherein R 1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group;
- X is a group —(CH 2)n—R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide. R1 is preferably selected from hydrogen and lower alkyl groups, especially methyl. More preferably R1 is methyl in
positions position 9. - The compounds used according to the present invention and their preparation are described in EP patent 0238459 and U.S. Pat. No. 4,990,510 which are incorporated herein by reference.
- A compound which has proven to be especially effective is the compound of the following formula II
- In the drawings:
- FIG. 1 shows the results obtained in an EAE model test.
- FIG. 2 shows the results obtained in an EAE rat model test with different doses of a compound used according to the present invention.
- FIG. 3 shows the effect of pre-treatment with a compound used according to the present invention.
- FIG. 4 shows the effect of after-treatment with a compound used according to the present invention.
- The EAE (experimental autoimmune encephalomyelitis) model is a generally accepted animal model for the acute MS symptoms ( (1) Ruuls et al, J. Immunology, 1996, 157, 5721-5731; (2) van der Medide et al, J. Neuroimmunology, 1998, 84, 14-23; (3) Smith et al, Nature Medicine,2000, 6, 1, 62-66). The model is based on Lewis rats that
day 0 are induced by 20 μg myeline peptide (MBP 68-86) och 2 mg of Myobacterium tuberculosis. After one week severe CNS symptoms appear that are by double blind examination given a value—a clinical score. The higher value, the more severe effect. The scale is 0-5. After some 14 days there is a peak in symptoms followed by a decline back to the normal situation. - The negative control has no treatment except the immunization (day 0) to induce the acute MS response. In FIG. 1 the results from the negative control, Interferon-beta and a compound used according to the present invention, 2,3-dimethyl(dimethylaminoethyl)-5H-indolo-(2,3-b)quinoxaline, (B-220) are shown. From the figure it can be seen that Interferon-beta has no reducing effect of the CNS symptoms. The lower curve represents the tested substance used according to the present invention, which substance surprisingly and unexpectedly reduces the CNS symptoms with 2/3.
- In the test Interferon-beta was administered daily with 3×10 5 U/animal which is a medium dose (2). The tested substance(B-220), was administered daily with 6 mg/animal, a dose that can be increased since the margin to toxic effects is wide and most likely further reduce the symptoms. It is to be noted that the acute toxicity of the tested substance used according to the present invention is low, which is exemplified with the following:
- LD 50, oral, rat; >800 mg/kg bw
- LD 50, intravenous, rat; >100 mg/kg bw
- NOEL, intravenous, rat; 12.5 mg/kg bw
- NOEL, cutaneous, rabbit; 200 mg/kg bw
- (NOEL=No Observable Effect Level)
- The chronic toxicity has been tested up to 270 days on mice and the substance has not induced toxicity, on the contrary the substance has protected the animals for different health effects.
- In the well established EAE rat model for multiple sclerosis (MS) a compound used according to the present invention, B-220, was shown to down-regulate the clinical symptoms (clinical score) in a dose dependent manner. The results are shown in FIG. 2. At the highest dose, 12 mg/animal, (lower curve) the onset is delayed approximate 4 days, the recovery starts approximate 3 days earlier and the total effect is dramatically lowered. A majority of the animals do not show any symptoms at all in this group. Symptom grading 1 is thus a very weak and mild effect while grading 3 is a severe paralysis. The intermediate curve illustrates a dose of 6 mg/animal and the onset is delayed approximate 2 days, the recovery starts approximate 2 days earlier and the total effect is substantially lower as compared to the control, highest curve, where no B-220 is added.
- In FIG. 3 pre-treatment with B-220 before the onset of the disease is shown. The highest curve is illustrating the control without any added B-220 while the lower curve is after administration of B-220 of 6 mg/animal. As seen from the Figure the pre-treatment results in a clear lowered and delayed MS effect. Administration of B-220 was from −7 to +7 days in relation to the onset of disease (day 0).
- In FIG. 4 after-treatment with B-220 starting from
day 7 from the time point when the disease was initiated (day 0) and throughout the experiment is shown wherein the highest curve is a control without any addition of B-220 and the lower curve is representing a dose of 6 mg/animal of B-220. As seen from the Figure the after-treatment with B-220 lowered the MS effect in the rats. - The vertical lines in both FIG. 3 and FIG. 4 represent mean±standard deviation.
- A suitable dosage range for humans is 1 to 50 mg/kg body weight.
Claims (18)
1. A method for the treatment of multiple sclerosis comprising administering to a patient in need of said treatment an amount effective therefor of a compound of formula I:
wherein R1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group;
X is a group —(CH2)n—R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms,
or a physiologically acceptable addition product thereof with an acid or halogen adduct.
2. The method according to wherein said compound is a physiologically acceptable addition product with an adduct of iodine, iodine monochloride or iodine monobromide.
claim 1
3. The method of , wherein R1 is methyl in positions 2 and 3 and hydrogen in the other positions, or a physiologically acceptable addition product thereof.
claim 1
4. The method of , wherein R1 in one of the positions 7-10 is hydroxy.
claim 3
5. The method of , wherein R1 in position 9 is hydroxy.
claim 4
6. The method of , wherein R1 in one of the positions 7-10 is hydroxy.
claim 2
7. The method of , wherein R1 in position 9 is hydroxy.
claim 6
8. The method of , wherein R1 in one of the positions 7-10 is hydroxy.
claim 1
9. The method of , wherein R1 in position 9 is hydroxy.
claim 8
10. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 1
11. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 2
12. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 3
13. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 4
14. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 5
15. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 6
16. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 7
17. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 8
18. The method of wherein X is CH2N(CH3)2 and R3 is hydrogen.
claim 9
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/784,302 US6333327B2 (en) | 2000-02-18 | 2001-02-16 | Method for the treatment of Multiple Sclerosis |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18337200P | 2000-02-18 | 2000-02-18 | |
| US09/784,302 US6333327B2 (en) | 2000-02-18 | 2001-02-16 | Method for the treatment of Multiple Sclerosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20010046996A1 true US20010046996A1 (en) | 2001-11-29 |
| US6333327B2 US6333327B2 (en) | 2001-12-25 |
Family
ID=26879045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/784,302 Expired - Fee Related US6333327B2 (en) | 2000-02-18 | 2001-02-16 | Method for the treatment of Multiple Sclerosis |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US6333327B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008502676A (en) * | 2004-06-17 | 2008-01-31 | オクシーファルマ エイビー | Alkyl-substituted indoloquinoxaline compounds |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE516133C2 (en) * | 1999-02-25 | 2001-11-19 | Lundblad Leif J I | Use of certain substituted indoloquinoxalins for the preparation of an agent for the protection of tissues, organs and cells during transplantation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8600260D0 (en) * | 1986-01-21 | 1986-01-21 | Lundblad Leif | SUBSTITUTED INDOLOKINOXALINES |
-
2001
- 2001-02-16 US US09/784,302 patent/US6333327B2/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008502676A (en) * | 2004-06-17 | 2008-01-31 | オクシーファルマ エイビー | Alkyl-substituted indoloquinoxaline compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| US6333327B2 (en) | 2001-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN119424616B (en) | GIP/GLP1 agonist compositions | |
| DE69233643T2 (en) | Use of anticytokin-containing pharmaceutical compositions for the therapy of multiple sclerosis | |
| DE69837324T2 (en) | TREATMENT OF MULTIPLE SCLEROSIS BY USING COPOLYMER-1 | |
| CA2339934C (en) | Medicine for multiple sclerosis | |
| JP2000247884A (en) | Arachidonic acid-induced skin disease treatment | |
| EP2442832A1 (en) | Compositions and methods for treatment of multiple sclerosis | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| WO2011086470A1 (en) | Treatment of multiple sclerosis | |
| RU2341261C2 (en) | Compositions containing epothilones, and application thereof for carcinoid syndrome treatment | |
| CA1053150A (en) | Method of suppressing gastric acid secretion by the oral administration of calcitonin | |
| US6333327B2 (en) | Method for the treatment of Multiple Sclerosis | |
| EP1261344B1 (en) | Use of indoloquinoxalines for the treatment of multiple sklerosis | |
| JP3415643B2 (en) | Drugs for muscular dystrophy | |
| JP2000501085A (en) | Combination of pentoxifylline and type I interferons for treating multiple sclerosis | |
| EP0190851A1 (en) | Improved antiinflammatory composition | |
| CN101094671A (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
| JPS58208231A (en) | Medicine containing cholecalsiferol derivative | |
| US6197818B1 (en) | Drug for treating diabetic nephrosis | |
| JP2005518438A (en) | Use of biosynthetic estriol diester prodrugs to treat autoimmune diseases | |
| Herrick et al. | Nervous system involvement in association with vasculitis and anticardiolipin antibodies in a patient with systemic sclerosis | |
| CN1254597A (en) | Antiswelling medicine | |
| EP0005074A1 (en) | A material and composition for reducing blood pressure | |
| US20150258073A1 (en) | INDICATION OF ANTHRA[2,1,c][1,2,5]THIADIAZOLE-6,11-DIONE COMPOUND IN ALLEVIATING PAIN | |
| JPH0656661A (en) | Anticataract agent | |
| DE60020635T2 (en) | Chronic myeloid leukemia therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: LUNDBLAD, LEIF J. I., SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MOLLER, LENNART;BERGMAN, JAN;REEL/FRAME:011890/0198 Effective date: 20010403 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| REMI | Maintenance fee reminder mailed | ||
| LAPS | Lapse for failure to pay maintenance fees | ||
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20131225 |